Related Experiment Video
Updated: May 29, 2026

08:51
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
Published on: February 19, 2021
Benign multiple sclerosis: a new definition of this entity is needed
Jorge Correale1, Isabel Peirano, Lucas Romano
1Department of Neurology, Institute for Neurological Research Raúl Carrea, FLENI, Buenos Aires, Argentina. jcorreale@fleni.org.ar
Summary
Many patients meeting benign multiple sclerosis (MS) criteria experience worsening cognitive and non-motor symptoms over time. Routine monitoring of these factors and MRI is crucial for accurate diagnosis and treatment in MS care.
Area of Science:
- Neurology
- Neuroimmunology
- Clinical Neuroscience
Background:
- Benign multiple sclerosis (BMS) is often defined by minimal physical disability.
- Longitudinal studies are needed to understand the full spectrum of BMS beyond physical limitations.
Purpose of the Study:
- To evaluate cognitive, social, and non-motor symptoms in a cohort of BMS patients.
- To assess changes in MRI findings over time in BMS patients.
- To determine the long-term disease course of patients meeting BMS criteria.
Main Methods:
- Prospective follow-up of 342 patients for approximately 11 years.
- Detailed assessment of 43 patients meeting BMS criteria (EDSS < 3 after 10 years).
- Yearly evaluations included neurological exams, neuropsychological testing, pain, fatigue, social functioning, and brain MRI.
Main Results:
- Over 80% of BMS patients showed worsening cognitive function, fatigue, pain, or depression.
- Significant increases in new or enlarging T2 lesions and other MRI abnormalities were observed in 74% of patients.
- Cognitive impairment (47%), depression (53.3%), and changes in pain (48.8%) were prevalent.
Conclusions:
- Current BMS diagnostic criteria may overestimate prevalence.
- Routine monitoring of non-motor symptoms and MRI is essential for accurate diagnosis.
- Improved diagnostic accuracy and therapeutic decisions are needed for this MS subgroup.
Related Concept Videos
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

